ImmunityBio Inc

-0.24 (-4.26%)
Debt Financing / Related, Earnings Announcements

Athenex Announces Agreement With ImmunityBio Regarding Dunkirk Manufacturing Facility

Published: 01/12/2022 14:19 GMT
ImmunityBio Inc (IBRX) - Athenex Announces Agreement With Immunitybio Regarding Dunkirk Manufacturing Facility.
Athenex Inc - Agreement for Immunitybio, to Assume Its Leasehold Interest in a Manufacturing Facility in Dunkirk, and Some Assets for About $38 Million.
Athenex Inc - Immunitybio Will Assume All Capital Expenditure and Hiring Obligations of Athenex Pursuant to Its Agreements With New York State.
Athenex Inc - Proceeds From Sale Will Be Used to Service Company's Debt Obligations.
Athenex - Immunitybio Has Entered Into a Preliminary Agreement With Athenex to Allow Aps Ability to Manufacture Its 503b Products at Dunkirk Facility.
Revenue is expected to be $0.03 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $0.03 Million
Next Quarter EPS Guidance is expected to be -$0.22

More details on our Analysts Page.